Early Versus Late Recurrence in Olfactory Neuroblastoma: A Multi-Institutional Analysis of Predictive Risk Factors.

Authors

Alexandria Harris, Anthony Tang, Nicholas Fung, Joao Paulo Almeida, Pierre-Olivier Champagne, Juan Fernandez-Miranda, Paul A Gardner, Peter Hwang, Aristotelis Kalyvas, Chirag Patel, Zara M Patel, Maria Peris Celda, Carlos D Pinheiro-Neto, Olabisi Sanusi, Carl H Snyderman, Brian D Thorp, Jamie J Van Gompel, Georgios Zenonos, Nathan T Zwagerman, Diana Bell, Edward C Kuan, Eric W Wang, Mathew Geltzeiler, Garret Choby

Published in

International forum of allergy & rhinology. Jul 09, 2026. Epub Jul 09, 2026.

Abstract

Olfactory neuroblastoma (ONB) exhibits variable recurrence patterns, with significant late recurrences occurring years after treatment. We investigated cutoff periods to define late recurrence and identified predictors that distinguish patients at risk of late recurrence from those considered cured.
From a multi-institutional cohort of 219 ONB patients treated at nine centers, we analyzed 77 patients with documented recurrence. Using a 48-month cutoff to define early (< 48 months) versus late (≥ 48 months) recurrence, we evaluated 35 clinical, anatomic, and treatment variables using Firth penalized logistic regression across three comparisons: (1) late versus early recurrence timing, (2) late recurrence versus no recurrence, and (3) early recurrence versus no recurrence.
Thirty-four of the 77 (44.2%) recurrences were classified as late. Among the 77 patients who recurred, smaller tumor volume (OR 0.243, p = 0.035) and lower novel Dulguerov staging (OR 0.802, p = 0.038) were associated with late, rather than early recurrence. When patients with late recurrence were compared to those who remained disease-free, radiographic skull base bone involvement was the strongest independent predictor (OR 2.90, 95% CI 1.14-8.64, p = 0.025), and this effect strengthened after adjusting for tumor volume (OR 3.80, p = 0.029). Pathologic dural invasion (OR 3.29, p = 0.013), Kadish stage (OR 2.02, p = 0.026), and T-stage (OR 1.32, p = 0.040) were also significant.
A 48-month cutoff effectively stratifies ONB recurrence risk. Skull base bone involvement independently predicts recurrence when compared to nonrecurrent cases and uniquely persists as a risk factor for late recurrence. These findings establish skull base bone involvement as a novel biomarker for risk-stratified surveillance protocols.

PMID:
42422976
Bibliographic data and abstract were imported from PubMed on 09 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.